ArticleStem cells translational medicine2020
Two-year outcomes of infants enrolled in the first-in-human study of amnion cells for bronchopulmonary dysplasia.
Article in Stem cells translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Cell-based therapies in preclinical models of necrotizing enterocolitis: a systematic review and meta-analysis.Stem cells translational medicine · 2025Pooled it
- Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants.Stem cells translational medicine · 2026Trial
- Progress in cell therapies for neonatal conditions: Proceedings of the Third Neonatal Cell Therapies Symposium (2025).Pediatric research · 2026Article
- Coagulation activation and hepatic engraftment of human amnion-derived cells after intraportal transplantation in rats.Regenerative medicine · 2025Article
- The role of amniotic epithelial cells in preterm birth: mechanisms and clinical implications.Frontiers in cell and developmental biology · 2025Review
- Reinitiating lung development: a novel approach in the management of bronchopulmonary dysplasia.Respiratory research · 2024Review
- Research hotspots and emerging trends in mesenchymal stem/stromal cells in bronchopulmonary dysplasia.Human cell · 2024Review
- Article
- Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022).Pediatric research · 2023Review
- Stem/Progenitor Cells and Related Therapy in Bronchopulmonary Dysplasia.International journal of molecular sciences · 2023Review
- Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases.Seminars in perinatology · 2023Review
- Review
- Assessing the impact of gestational age of donors on the efficacy of amniotic epithelial cell-derived extracellular vesicles in experimental bronchopulmonary dysplasia.Stem cell research & therapy · 2022Article
- Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.Pediatric research · 2022Review
- Clinical perspective on the use of human amniotic epithelial cells to treat congenital metabolic diseases with a focus on maple syrup urine disease.Stem cells translational medicine · 2021Article
- A protocol for cell therapy infusion in neonates.Stem cells translational medicine · 2021Article
- Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.Stem cell reviews and reports · 2021Article
- MSC Based Therapies to Prevent or Treat BPD-A Narrative Review on Advances and Ongoing Challenges.International journal of molecular sciences · 2021Review
- Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.International journal of molecular sciences · 2021Review
- Crescentic Glomerulonephritis: Pathogenesis and Therapeutic Potential of Human Amniotic Stem Cells.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported on the immediate safety and neonatal outcomes of six premature infants with severe bronchopulmonary dysplasia (BPD) who were administered human amnion epithelial cells (hAECs). One infant died in the neonatal period due to unrelated causes. In this study, we aimed to assess the long-term safety and follow-up outcomes of the five surviving infants until 2 years corrected age (CA). hAECs were administered intravenously at a dose of 1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.